Skip to main content
Indian stocks: Visit www.stage2stocks.com →

QuidelOrtho Corporation

Stage 4 · Declining · week 6

As of Oct 22, 2026, QuidelOrtho is in Stage 4, the downtrend phase, now in week 6 (since Sep 11, 2026). It closed at $13.48, 61.9% below its 52-week high and below its 200-day average, which is falling.

QuidelOrtho Corporation provides diagnostic testing solutions. More about the company

$13.48
-4.26% today
$924M · Small cap
Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Accelerating ⇈

Edge

—

Is QDEL early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…
Stage Cycle Timeline2023-08-16 → 2026-10-22
S4 20w
S4 27w
S4 15w
S4 17w
2023-08-162026-10-22
S1S2S3S4Setup score (0–10, dashed line at 5)
S4 20w → S1 6w → S4 27w → S1 9w → S4 9w → S1 1w → S2 9w → S3 2w → S4 15w → S1 2w → S4 10w → S1 6w → S4 7w → S1 3w → S2 5w → S3 1w → S4 17w → S1 9w → S4 6w current
Total tracked: 165 weeks across 19 stage runs.

QDEL among Medical Devices95th of 141 by relative strength

All 141 →
Stocks in Medical Devices ranked by relative strength, with stage and one-month change
#StockStageRS1M
1TXGStage 2 · wk 4899−7.8%
2RCELStage 2 · wk 1398+40.8%
3BFLYStage 2 · wk 2698−26.0%
4HAEStage 2 · wk 1796+8.7%
5GKOSStage 2 · wk 2596+15.1%
6AXGNStage 3 · wk 295−15.3%
7NEOGStage 2 · wk 1495−11.7%
8BVSStage 2 · wk 1595+10.5%
…95QDELStage 4 · wk 621+30.4%
vs 52W High
-61.9%
$9.96 lo$35.38 hi
61.9% below 52W high, deep Stage 4 damage
In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.
Stage Maturity
Week 6
1w13w26w
Week 6, early Stage 4 decline
How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.
vs 200 DMA
-20.0%
200 DMA: $16.86 · sloping down
In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.
Rel Volume
0.95x
vs 50-day avg
High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.
Trend Health
↑ ⇈
Short-term trend rising strongly, and accelerating
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
+30.4%
3M
-16.0%
6M
+19.9%
YTD
-53.2%
1Y
-54.8%
Scan Membership
Breakout Watch
Latest: 2025-01-07
8 appearances in last 60 days. First seen: 2019-04-05.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-22S4
Wk 6 · Vol 0.95x
2026-10-21S4
Wk 6 · Vol 1.78x
2026-10-20S4
Wk 6 · Vol 1.55x
2026-10-19S4
Wk 6 · Vol 0.81x
2026-10-16S4
Wk 6 · Vol 1.00x
2026-10-15S4
Wk 5 · Vol 1.13x
2026-10-14S4
Wk 5 · Vol 1.22x
2026-10-13S4
Wk 5 · Vol 1.77x
2026-10-12S4
Wk 5 · Vol 1.55x
2026-10-09S4
Wk 5 · Vol 2.19x
2026-10-08S4
Wk 4 · Vol 1.56x
2026-10-07S4
Wk 4 · Vol 1.55x
Moving averages & range
50 DMA
$12.84
200 DMA
$16.86
52W High
$35.38
52W Low
$9.96
5D Low
$12.76
Resistance levels (recent highs)
20d High
$14.21
60d High
$17.71
120d High
$18.27
250d High
$35.38
Next resistance
+5.4%
to 20d High
ROE
-45.9%
Profit margin -39.2%
Dividend Yield
0.00%
P/B 0.5

QuidelOrtho: quick answers

What stage is QuidelOrtho in?

As of Oct 22, 2026, QuidelOrtho (QDEL) is in Stage 4, the downtrend phase. It entered Stage 4 on Sep 11, 2026 and is in week 6. What the four stages mean

Is QuidelOrtho in an uptrend?

No. QuidelOrtho is in a Stage 4 downtrend. It trades 20.0% below its 200-day average, which is falling.

How far is QuidelOrtho from its 52-week high?

QuidelOrtho closed at $13.48 on Oct 22, 2026, 61.9% below its 52-week high of $35.38. Its 52-week low is $9.96.

How has QuidelOrtho performed over the past year?

As of Oct 22, 2026, QuidelOrtho is down 54.8% over the past year and down 53.2% so far in 2026.

Which sector and industry is QuidelOrtho in?

QuidelOrtho is in the Medical Devices industry, part of the Health Care sector.

About this companyHealth Care· Medical Devices

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, to measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point of Care business unit provides instruments and tests to provide rapid results across a continuum of POC settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, Japan and Asia Pacific, and Latin America. The company was incorporated in 1979 and is headquartered in San Diego, California.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.